Search

everythinglearnresearchcommunity

for

Search:↓

The user is using minoxidil and topical finasteride for hair loss and is seeking advice on whether to use a derma pen or derma stamp for microneedling, including the appropriate length and frequency. They previously stopped oral finasteride due to side effects.

A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.

The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.

The conversation discusses the duration of hair shedding caused by RU58841. The user is stressed and seeking information on how long the shedding phase lasts.

A 20-year-old with a family history of male pattern baldness is seeking advice on using finasteride due to an allergy to minoxidil. They are considering whether to use topical or oral finasteride and what dosage to take.

A person struggling with hair loss is using treatments like dutasteride, oral minoxidil, and has had a hair transplant but remains deeply unhappy. Others suggest alternative treatments, acceptance, and focusing on other life aspects, emphasizing mental health and therapy.

A 29-year-old male experienced significant hair regrowth over 8 months using a protocol of oral Minoxidil, Dutasteride, Pyrithione Zinc Shampoo, and peptides GHK-CU, BPC-157, and TB-500. The treatment led to improved scalp coverage, reduced hair loss, and thicker hair, although results may vary for others.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Clascoterone (Breezula) shows promising hair growth results, but skepticism remains due to past disappointments with new treatments. It may be a good alternative for those who can't tolerate finasteride or dutasteride, and can potentially be combined with them and minoxidil for better results.

A 17-year-old is concerned that taking finasteride might affect facial bone growth and is considering switching to topical finasteride due to its reduced systemic effects. They are also using oral minoxidil and exploring other hair loss treatments like microneedling and ketoconazole shampoo.

Oral minoxidil dosing should be based on body weight to minimize side effects, with higher doses increasing risks like pericardial effusion. Combining oral minoxidil with topical treatments and finasteride can improve hair growth, but regular heart health monitoring is essential.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

2.5mg oral minoxidil can be effective for hair regrowth, but 5mg often shows more dramatic results. Users at Norwood 2 using 1mg finasteride may see modest regrowth with 2.5mg, and it's suggested to give it a proper trial.

A user in their 40s is using finasteride every other day and ketoconazole shampoo for hair loss, considering adding topical minoxidil for further regrowth, including on eyebrows. They are advised to continue with the current regimen for a few more months before reassessing and to be cautious with minoxidil due to its application challenges and potential risks to pets.

Starting Minoxidil now won't affect future Finasteride gains; they work differently and can be used together. It's suggested to start Minoxidil to maintain hair health until Finasteride can be started, and consider additional treatments like Ketoconazole shampoo, derma rolling, and rosemary oil for support.

Topical finasteride concentrations are likely much higher than necessary for effective follicular DHT suppression, with current standards being 100-1000 times above the theoretical minimum. Lower concentrations (0.001-0.0025%) might still work locally while minimizing systemic exposure.

Celebrities may use Dutasteride for hair loss, but Finasteride is more commonly used due to its extensive research and long-term safety. Dutasteride is considered more effective but is often used off-label or as a secondary option.

Users discuss the effectiveness of low-dose topical finasteride (0.005-0.05%) for hair loss, often combined with minoxidil. Some report stable results or new growth, but it's unclear if improvements are due to finasteride or minoxidil.

Common misconceptions about hair loss treatments include the belief that lower doses of finasteride are as effective as higher doses, and that ketoconazole is effective for androgenetic alopecia without scalp issues. Additionally, minoxidil's effects can be seen sooner than commonly thought, and topical dutasteride is effective.

The conversation is about finding non-alcoholic minoxidil options in India due to irritation from propylene glycol-based formulations. Suggestions include Tugain 5% foam, Morr Max 5%, minoxidil gel, and Morr F Aqua plus, with OP avoiding finasteride due to side effects.

The conversation is about using coenzyme Q10 for hair loss alongside dutasteride. The effectiveness of coenzyme Q10 for treating androgenetic alopecia is questioned due to a lack of evidence.

Oral minoxidil and oral dutasteride are considered effective for hairline and hair recovery, but results vary. Topical minoxidil can still be used for beard and eyebrows even when taking oral versions.

The user has been on finasteride for 9 months and is unsure if it's effective, considering adding minoxidil or dutasteride. Other users suggest adding minoxidil for regrowth and discuss the pros and cons of oral versus topical treatments.

The user shared their 5-year hair regrowth journey using oral finasteride, oral dutasteride, topical and oral minoxidil, and a hair transplant. They experienced significant hair improvement without major side effects, although RU58841 was not effective for them.

A new light therapy claims to reduce hair loss markers by 92% using a specific wavelength range. Users discuss the cost and effectiveness of devices, with some expressing skepticism and others considering alternative treatments like red light therapy and vitamin D exposure.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

The conversation discusses alternatives for hair loss treatment for someone allergic to finasteride, suggesting options like hair systems, topical anti-androgens such as CB-03-01, RU58841, and kx-826. It highlights the challenges faced by individuals allergic to anti-androgen inhibitors and the need for more information on this topic.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.